Identification of CYP2C9, VKORC1 genotypes and recommendation of warfarin dose for Vietnamese cardiovascular patients

Please use this identifier to cite or link to this item: https://dspace.ctu.edu.vn/jspui/handle/123456789/31937

Full metadata record

DC Field	Value	Language
dc.contributor.author	Nguyen, Dang Ton	-
dc.contributor.author	Nguyen, Thị Thanh Hoa	-
dc.contributor.author	Nguyen, Phan Anh	-
dc.contributor.author	Vu, Phuong Nhung	-
dc.contributor.author	Le, Thi Bich Thao	-
dc.contributor.author	Nguyen, Hai Ha	-
dc.date.accessioned	2020-08-20T01:28:55Z	-
dc.date.available	2020-08-20T01:28:55Z	-
dc.date.issued	2019	-
dc.identifier.issn	1811-4989	-
dc.identifier.uri	https://dspace.ctu.edu.vn/jspui/handle/123456789/31937	-
dc.description.abstract	Warfarin is a well-known anticoagulant that capable of reducing the activity of vitamin K-dependent clotting factors. lt has been widely used for cardiovascular patients. However, patient's genotypes of CYP2C9 and VKORC1 remarkably affects the metabolism of warfarin. This study aims to identily the CYP2C9 and VKORC1 genotypes of 96 Vietnamese patients suffering cardiodynia or myocardial infarction and establish their daily warfarin dose.	vi_VN
dc.language.iso	en	vi_VN
dc.relation.ispartofseries	Journal of Biotechnology;№ 17(04) .- Page.589-594	-
dc.subject	Warfarin	vi_VN
dc.subject	Pharmacogenetics	vi_VN
dc.subject	CYP2C9 gene	vi_VN
dc.subject	VKORC1 gene	vi_VN
dc.subject	PCR-RFLP	vi_VN
dc.title	Identification of CYP2C9, VKORC1 genotypes and recommendation of warfarin dose for Vietnamese cardiovascular patients	vi_VN
dc.type	Article	vi_VN
Appears in Collections:	Công nghệ sinh học

Files in This Item:

File	Description	Size	Format
_file_ Restricted Access		1.74 MB	Adobe PDF
Your IP: 3.129.23.110

LRC Digital repo